Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: Results from the British Society for Rheumatology Biologies Register

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 209-215

  Harrison, M J ^a   Dixon, W G ^a   Watson, K D ^a   King, Y ^a   Groves, R ^b   Hyrich, K L ^a   Symmons, D P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PSORIASIS; REGISTER; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58849160468     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.087288     Document Type: Article

References (38)

1. Feldmann M, Brennan FM, Williams RO, Woody JN. Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti- TNF therapy of rheumatoid arthritis. Sesf Pratt Res Clin Rheumatol 2004;18:59-80.
2. Mease P. TNFα therapy in psoriatic arthritis and psoriasis, Ann Rheum Dis 2004;63:755-8.
3. Taurog JD. The spondyloarthritides. In: Fauci AS. Langford CA. Kasper DL, Longo DL, Braunwald E. Hauser SL, et al. eds Harrison's rheumatology. New York, USA: McGraw-Hill, 2006:139-55.
4. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9
6. Weinblatt ME, Keystone EC. Furst DE, Moreland LW. Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial Arthritis Rheum 2003;48:35-45
7. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al Infliximab induction therapy for patients with severe plaque-type psoriasis a randomized, double-blind, placebo-controlled trial, J Am Acad Dermatol 2004;51:534-42
8. Papp KA, Tyring S, Lahta M, Prinz J, Griffiths CE, Nakamshi AM, et al A global phase III randomized controlled trial of etanercept in psoriasis safety, efficacy, and effect of dose reduction. Br J Dermatoi 2005;152:1304-12
9. Kyle S. Chandler D, Griffiths CEM, Helliwell P, Lewis J, Mclnnes I, et al. Guideline for anti-TNF-α therapy in psoriatic arthritis Rheumatology 2005,44390-7
10. Beuthien W, Mellinghoff HU. von KJ. Skin reaction to adalimumab Arthritis Rheum 2004;50:1690-2
11. Dereure O, Guillot B. Jorgensen C, Cohen JD, Combes B, Guilhou JJ Psoriatic lesions induced by antitumour necrosis factor-α treatment two cases Br J Dermatoi 2004;151:506-7
12. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoa arthritis: a prospective study Arthritis Res Ther 2005;7:R666-76
13. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment comment on the article by Beuthien et al Arthritis Rheum 2005;52:1333 -4
14. Sfikakis PP, lliopoulos A. Elezoglou A, Kittas C, Stratigos A Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction Arthritis Rheum 2005;52:2513-18
15. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H. et al New onset c exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann Rheum Dis 2005;65:405-7
16. Sari I, Akar S, Birhk M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-α-induced psoriasis. J Rheumatol 2006;33:1411-14.
17. Goncalves DP, Launndo I, Scheinberg MA The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol 2006;12:262
18. Aslanidis S, Pyrpasopoulou A, Leontsini M, Zamboulis C, Anti-TNF-α-inauced psoriasis: case report of an unusual adverse event. Int J Dermatol 2006;45:982-3
19. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al Psoriasis induced by tumor necrosis factor-α antagonist therapy a case series J Rheumatoi 2007;34:380-5.
20. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31
21. Ubriani R, Van Voorhees AS Onset of psoriasis during treatment with TNF-α antagonists: a report of 3 cases. Arch Dermatol 2007;143:270-2
22. Starmans-Kool MJ, Peeters HR. Houben HH. Pustular skin lesions m patients treated with infliximab: report of two cases Rheumatol Int 2005;25:550-2
23. Michaelsson G, Kaiermo U. Michaelsson A, Hagforsen E Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-α in the normal palmar eccrine sweat duct Bi J Dermatoi: 2005;153:1243-4.
24. Roux CH, Brocq O. Leccia N, Giacchero D, Breuil V, Albert C, et al New-onset psoriatic palmoplantans pustulosis following infliximab therapy a class effect J Rheumatol 2007;34:34-7.
25. Silman A, Symmons D, Scott DG, Griffiths I British Society for Rheumatoiogy, Biologies Register Ann Rheum Dis 2003;62(Suppl 2) ii28-9
26. Ledingham J, Deighton C, British Society for Rheumatology Standards GaAWG Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001. Rheumatology 2005;44:157-63.
27. Prevoo MLL, Vanthof MA, Kuper HH, Vanleeuwen MA, Vandeputte LBA, Vannel PLCM. Modified disease-activity scores that include 28-joint counts - development and validation in a prospective longitudinal-study of patients with rheumatoid-arthritis Arthritis Rheum 1995;38:44-8
28. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis Br J Rheumatol 1986;25:206-9
29. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement cnteria that include simplified joint counts Arthritis Rheum 1998;41:1885-50
30. Stata Corporation. Stata statistical software College Station, Texas. USA Stata Corporation, 2006
31. Wang B, Fujisawa H, Zhuang L, Kondo S, Shivji GM. Kim CS. et al Deoressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75. J Immunol 1997;159: 6148-55
32. Groves RW, Allen MH, Ross EL, Barker JN, MacDonald DM Tumour necrosis factor α is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression, Br J Dermatol 1995;132:345-52.
33. Fiorentino DF. The yin and yang of TNF-α inhibition. Arch Dermatol 2007.143 233-6
34. RHchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis 2006;65:1541-4
35. Padial MA, varez-Ferreira J, Tapia B, Blanco R, Manas C, Blanca M, et al Acute generalized exanthematous pustulosis associated with pseudoephednne Br J Dermatol 2004;150:139-42
36. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005;202:135-43.
37. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 2005;102:3372-7.
38. Peek R, Scott-Jupp R, Strike H, Clinch J, Ramanan AV. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 2006;65:1259.